APL-1030

N/A

Report date: 2023/01/08 10:16:32
NME

Base Information

Drug NameAPL-1030
Drug Alias NameAPL-1030
ClassificationSmall molecules
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsNeurodegenerative Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesApellis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesApellis Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeurodegenerative Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A